Oxaliplatin Hexal

Oxaliplatin, the active ingredient in Oxaliplatin Hexal, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically in combination with other chemotherapeutic agents, and is administered to adult patients.

GNH USA supplies Oxaliplatin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin Hexal is used in colorectal cancer treatment protocols that target the DNA replication pathway.

- Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: Used off‑label in combination regimens for advanced disease. - Pancreatic cancer: Investigated in clinical trials as part of multi‑drug protocols.

Oxaliplatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: Frequent gastrointestinal upset during or after infusion. - Peripheral neuropathy: Tingling or numbness in the hands and feet, often dose‑related. - Diarrhea: Loose stools that may require supportive care. - Fatigue: Generalised tiredness experienced during treatment cycles. - Elevated liver enzymes: Mild, transient increases in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm requiring immediate medical intervention. - Hematologic toxicity: Significant neutropenia or thrombocytopenia increasing infection or bleeding risk. - Cardiac events: Rare arrhythmias or myocardial ischemia observed during infusion. - Acute pulmonary toxicity: Uncommon lung inflammation presenting with dyspnoea. - Renal impairment: Deterioration of kidney function, particularly with pre‑existing renal disease.

When handling Oxaliplatin Hexal, clinicians should observe several safety measures.

- Pre‑infusion assessment: Verify patient’s baseline blood counts and organ function. - Hydration status: Ensure adequate intravenous fluids to reduce renal toxicity risk. - Neuropathy monitoring: Conduct regular neurological examinations during treatment. - Concomitant medications: Review for agents that may exacerbate myelosuppression. - Pregnancy and lactation: Avoid use unless benefits clearly outweigh risks. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use with high‑dose cisplatin or aminoglycosides can increase kidney injury. - Myelosuppressive chemotherapy: Combining with other bone‑marrow suppressors may cause severe cytopenias.

Moderate Interactions (Monitor Closely): - Anticoagulants: May enhance bleeding risk; monitor coagulation parameters.\n- Antiemetics: Certain serotonin‑receptor antagonists can alter oxaliplatin clearance. - CYP450 inducers: May reduce plasma concentrations of oxaliplatin. - Herbal supplements: St. John’s wort